ライフサイエンスコーパス: human albumin

1 00 IU in total over 4 days) or a placebo (1% human albumin).

2 cid 2-phosphate and rice-derived recombinant human albumin.

3 nomodulatory molecule from the N terminus of human albumin.

4 no inflammatory signs in any eyes exposed to human albumin.

5 uction of human alpha-feto-protein (AFP) and human albumin.

6 ity copper-binding site of the N-terminus of human albumin.

7 hosphate (DFP), and sarin covalently bind to human albumin.

8 to achieve affinity capture of lysozyme and human albumin.

9 Control animals received human albumin.

10 h preserved structural features had taken up human albumin.

11 ved, with BSA binding close to twice that of human albumin.

12 Animals were treated with either 25% human albumin, 1.25 g/kg, or saline vehicle i.v. at 90 m

13 Human albumin (25%, 2.5 mg/kg; n=12) or vehicle (0.9% sa

14 tated Ringer's solution, dextran, hespan, 5% human albumin, 25% human albumin, 3.5% hypertonic saline

15 tion, dextran, hespan, 5% human albumin, 25% human albumin, 3.5% hypertonic saline, and 7.5% hyperton

16 Treatment with human albumin administered intravenously in the immediat

17 , HepG2, or Chinese hamster ovary cells with human albumin (ALB)/human apoB chimeric cDNA constructs:

18 oGen) with that of active control (sonicated human albumin [Albunex]) for left ventricular (LV) cavit

19 Notably, upon transplantation, human albumin and alpha1-antitrypsin (A1AT) in mouse ser

20 hepatocytes contained significant amounts of human albumin and alpha1-antitrypsin.

21 Incubations of alachlor (0-1000 microM) with human albumin and bovine serum albumin (BSA) resulted in

22 tion sites (12 lysines and 2 asparagines) on human albumin and highlight reaction specificity for the

23 sing concentrations of human proteins (e.g., human albumin and human C3a) can be measured in the bloo

24 g, genetic fusion polypeptide of recombinant human albumin and interferon alfa-2b, in patients with c

25 ps of 5 each to receive 2 different doses of human albumin and nonhuman nucleic acids and their respe

26 Isovolemia was maintained with 5% human albumin and/or autologous plasma.

27 oses of 50 units/kg every 12 hrs, or 5 mg/kg human albumin as placebo.

28 er a single infusion of CDP571 (5 mg/kg), or human albumin as placebo.

29 Presence of human albumin at physiologic concentration in the cultur

30 sticides and nerve agents bind covalently to human albumin at Tyr411.

31 ciated with an antibody response against the human albumin-based carrier protein, which was prevented

32 We now extend these studies to show that human albumin, but not ceruloplasmin, mediates the conve

33 We have engineered human albumin by introducing single point mutations in t

34 In animals treated with human albumin, cortical neurons with preserved structura

35 l, a nanoparticle conjugate of paclitaxel to human albumin, exhibits efficacy in pancreatic cancer, n

36 Colonies of cytokeratin-18 and human albumin-expressing cells were present in the liver

37 Human albumin expression was detected only in CCl(4)-tre

38 Additionally, we find that human albumin follows a domain associated unfolding path

39 Thus, the affinity of human albumin for bilirubin is not constant, but varies

40 onstrates that DDFP is superior to sonicated human albumin for LV cavity opacification, endocardial b

41 was used to study the reaction of CBDP with human albumin, free tyrosine, and human butyrylcholinest

42 with a single bolus injection of recombinant human albumin-fused infestin-4 (rHA-Infestin-4) on traum

43 s, lactobacilli, Mycoplasma hominis, and the human albumin gene (for quality control).

44 composed of IFN-alpha2b genetically fused to human albumin, has an extended half-life and early evide

45 e albumin group was administered 25 g of 25% human albumin in 0.9% saline every 8 hrs for a total of

46 Vapor phase TDI was found to react with human albumin in a dose-dependent manner, with up to 18

47 Further immunohistochemistry of human albumin in retrieved cell aggregates confirmed the

48 subgroups of mice were resuscitated with 4% human albumin in the absence or presence of vehicle, val

49 The transplanted hiPSC-EB-HLCs secreted human albumin into the host plasma throughout the examin

50 Human albumin is thought to hydrolyze esters because mul

51 ells with human-specific gene expression and human albumin levels in murine serum that were higher fo

52 thod was evaluated with data from technetium human albumin macroaggregates ((99m)Tc-MAA) evaluations

53 Human albumin made a covalent bond with CBDP, adding a m

54 pper-62-PTSM congeners with less avidity for human albumin may prove more suitable for evaluation of

55 Treatment with human albumin may provide direct neuronal protection.

56 We hypothesized that sonicated 5% human albumin microbubbles (Albunex) adhere to disrupted

57 Human albumin or plasma was treated with organophosphoru

58 perfusion: Hextend (hetastarch solution); 5% human albumin; or lactated Ringer's solution.

59 Both bovine and human albumin prevented T/HS lymph-induced HUVEC cytotox

60 Intracameral injection of human albumin protein did not cause ocular inflammation.

61 - 22, and 467 +/- 47 nm for rat, rabbit, and human albumin, respectively.

62 ein linking coagulation factor IX (FIX) with human albumin (rIX-FP) has been developed to facilitate

63 e magnitude of injury in T/HS rats receiving human albumin (shed blood + 0.12, 0.24, or 0.36 g/kg) or

64 on to the ischemic area of human PRP lysate, human albumin solution (HSA), saline or no treatment at

65 Taken together, human albumin solution infusions may be used to reduce c

66 In vivo administration of human albumin solution to these patients significantly i

67 solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24

68 by 2 mg/kg over 24 h) or placebo (0.2 mg/mL human albumin solution) in addition to conventional medi

69 osemicarbazone), interact more strongly with human albumin than dog albumin.

70 thelial and biliary duct cells, and secreted human albumin that was detected in circulation.

71 Human albumin therapy within the first 4 h is highly neu

72 orm takes advantage of the long half-life of human albumin to provide a new treatment approach that a

73 gree of IgG extravasation was not changed by human-albumin treatment.

74 ble-blind, controlled study in which 25 g of human albumin vs. placebo was administered intravenously

75 ssure following a fixed intravenous bolus of human albumin was analyzed, first before start of, and t

76 The binding of DFP to Tyr411 of human albumin was confirmed by electrospray tandem mass

77 rotein were expressed in the mouse liver and human albumin was detected in the serum of mice that had

78 xidation of A1-1 was modest and oxidation of human albumin was extensive in the presence of HYP, as m

79 Human albumin was not expressed in the starting stem cel

80 The increase with 5% human albumin was only 2.2 x baseline, and 25% albumin d

81 Fatty acid-free human albumin was treated with 0.5 mm p-nitrophenyl acet

82 globulins (IgG), rat albumin and (exogenous) human albumin was used to study blood-brain barrier chan

83 We exposed podocytes to recombinant human albumin, which lacks lipids and proteins that bind